Format

Send to

Choose Destination
Surg Oncol Clin N Am. 2011 Apr;20(2):273-9, vii-viii. doi: 10.1016/j.soc.2010.11.002. Epub 2010 Dec 13.

Radiofrequency ablation of neuroendocrine hepatic metastasis.

Author information

1
Medical College of Wisconsin, Division of Surgical Oncology, 9200 West Wisconsin Avenue, Milwaukee, WI 53226-3596, USA. tcgamblin@mcw.edu

Abstract

Neuroendocrine cancer commonly metastasizes to the liver and often presents as unresectable disease. Liver resection or debulking most of the tumor provides a survival advantage for patients. Whether used alone or in combination with resection, radiofrequency ablation provides a unique tool to destroy metastases to the liver and spare hepatic parenchyma. Although randomized trials are lacking, retrospective series provide promising data to consider radiofrequency ablation in the management of hepatic neuroendocrine metastases.

PMID:
21377583
DOI:
10.1016/j.soc.2010.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center